跳至主要内容
临床试验/NCT06696235
NCT06696235招募中4 期

AcceleRatEd vs. StandarD ContinUous Renal ReplaCement ThErapy for Patients With Cardiogenic Shock Undergoing Veno-arterial ExtraCorporeal Membrane Oxygenator: Randomized-Controlled Trial

Samsung Medical Center2 个研究点 分布在 1 个国家目标入组 408 人开始时间: 2024年12月31日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
招募中
入组人数
408
试验地点
2
主要终点
all-cause mortality or RRT dependence

研究概览

简要总结

This study was designed to compare the safety and efficacy of early continuous renal replacement therapy with standard continuous renal replacement therapy in the presence of acute kidney injury (stage 2 or greater acute kidney injury according to the KDIGO [The Kidney Disease: Improving Global Outcomes] classification) in patients with advanced cardiogenic shock on extracorporeal membrane oxygenation.

详细描述

Patients with cardiogenic shock who are placed on extracorporeal membrane oxygenation devices often have increased afterload due to the retrograde arterial flow of the device, resulting in increased left ventricular filling pressures, and optimal full-load management in these patients may be important to improve prognosis. Previous observational studies have reported that the use of renal replacement therapy for full-load management in patients with cardiogenic shock on extracorporeal membrane oxygenation is effective and improves patient survival in cases of severe renal dysfunction when fluid volume reduction is maintained. However, to date, there have been no randomized controlled studies to identify the optimal timing of renal replacement therapy in patients with cardiogenic shock on extracorporeal membrane oxygenation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

盲法说明

Open Label Trial

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •The subject must be at least 19 years of age.
  • •Patients presented with CS (Society for Cardiovascular Angiography and Interventions [SCAI] Shock classification C, D or E) * who requiring VA-ECMO.
  • •Classic CS (Stage C) was defined as the following criteria. A. Systolic blood pressure less than 90 mmHg for more than 30 min or catecholamines required to maintain pressure more than 90 mmHg during systole. B. Sign of pulmonary congestion
  • •C. Sign of impaired organ perfusion with at least one of the following:
  • •altered mental status.
  • •cold, clammy skin and extremities.
  • •oliguria with urine output < 30ml/h.
  • •serum lactate > 2.0 mmol/l.
  • •SCAI Shock classification D is defined as failure to respond to initial interventions with clinical deterioration of classic CS or SCAI Shock classification E is defined as cardiac arrest with ongoing cardiopulmonary resuscitation requiring VA-ECMO
  • •Patients in the first 48 hours of CS developing AKI with at least one criterion (Characteristic of the stage 2 AKI according to Kidney Disease: Improving Global Outcomes [KDIGO] classification)
  • •A 2-fold or over increase in serum creatinine relative to baseline
  • •A reduction in urine output of ≤0.5 ml/kg/h for ≥ 12 hours

排除标准

  • •Other causes of shock (hypovolemia, sepsis, obstructive shock).
  • •Criteria mandating CRRT initiation: acute kidney injury prior to enrollment caused by any reason, at least one of the following criteria is met.
  • •serum potassium > 6.5 mmol/L
  • •serum potassium> 6.0 mmol/L persisting despite medical treatment.
  • •metabolic acidosis (pH < 7.15 and PaCO2 < 35 mmHg or serum bicarbonate < 12 mmol/L)
  • •blood urea nitrogen level ≥100 mg/dL.
  • •diuretics refractory volume overload or pulmonary edema
  • •Unwitnessed out-of-hospital cardiac arrest with persistent Glasgow coma scale <8 after the return of spontaneous circulation.
  • •Chronic kidney disease (CKD) with estimated glomerular filtration rate (eGFR)<30 mL/min/1.73m2 or end-stage kidney disease under dialysis
  • •Kidney transplant within the past 365 days
  • •Receipt of any RRT in the preceding 2 months
  • •Known heparin intolerance.
  • •Other severe concomitant disease with limited life expectancy < 6 months
  • •Pregnancy or breastfeeding
  • •Do not resuscitate wish.
  • •Presence of a drug overdose or dialyzable toxin that necessitates RRT.
  • •Presence or strong clinical suspicion of post-renal AKI duet to obstruction, rapidly progressive glomerulonephritis, vasculitis, thrombotic microangiopathy or acute interstitial nephritis
  • •Clinical decision by a responsible physician to immediately start RRT.
  • •Clinical decision by a responsible physician to defer RRT.

研究组 & 干预措施

Accelerated initiation of CRRT

Experimental

In the accelerated-strategy group, RRT is initiated as soon as possible and within 6 hours after patients have met full eligibility criteria.

干预措施: Early initiation of continuous renal replacement therapy (Device)

Standard initiation of CRRT

Active Comparator

Clinicians were discouraged from initiating RRT until the development of one or more of the following criteria.

  • Serum potassium > 6.5 mmol/L
  • Serum potassium> 6.0 mmol/L persisting despite medical treatment
  • Metabolic acidosis (pH < 7.15 and PaCO2 < 35 mmHg or serum bicarbonate < 12 mmol/L)
  • Blood urea nitrogen level ≥100 mg/dL
  • Oliguria (≤0.3 ml/kg/hour) or anuria for 48h or more
  • Diuretics refractory fluid overload or pulmonary edema

干预措施: Standard initiation of continuous renal replacement therapy (Device)

结局指标

主要结局

all-cause mortality or RRT dependence

时间窗: 90 days after patient enrollment

次要结局

  • In-hospital mortality(Up to 30 days)
  • In-hospital cardiac mortality(Up to 30 days)
  • VA-ECMO weaning success(Up to 30 days)
  • Time to VA-ECMO weaning(Up to 30 days)
  • Critical limb ischemia(Up to 30 days)
  • Access site major bleeding(Up to 30 days)
  • CPC 3-5(Up to 30 days)
  • Length of intensive-care unit stay(Up to 30 days)
  • Length of hospital stay(Up to 30 days)
  • Duration of mechanical ventilation(Up to 30 days)
  • Duration of RRT(Up to 30 days)
  • all-cause mortality(90 days & 12 months after patient enrollment)
  • cardiac mortality(90 days & 12 months after patient enrollment)
  • Requirement of cardiac replacement therapy(90 days & 12 months after patient enrollment)
  • re-hospitalization due to heart failure(90 days & 12 months after patient enrollment)
  • re-hospitalization due to any cause(90 days & 12 months after patient enrollment)
  • cerebrovascular accident(90 days & 12 months after patient enrollment)
  • RRT dependence(90 days & 12 months after patient enrollment)
  • Serum creatinine and eGFR(90 days & 12 months after patient enrollment)
  • major bleeding (BARC type 3, or 5)(90 days & 12 months after patient enrollment)
  • clinically meaningful bleeding (BARC type 2, 3, or 5)(90 days & 12 months after patient enrollment)
  • Patients in the standard strategy group who received emergency RRT before 48 hours, according to criterion(Up to 48 hours)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Jeong Hoon Yang

Professor

Samsung Medical Center

研究点 (2)

Loading locations...

相似试验